Роль лікування вітаміном D у клінічній оцінці остеопорозу у хворих на хронічну хворобу нирок

DOI: https://doi.org/10.31450/ukrjnd.1(81).2024.09
Ключові слова: остеопороз, вітамін D, кальцитріол, ниркова остеодистрофія, кальцидіол

Анотація

Поширеність дефіциту вітаміну D є надзвичайно високою серед пацієнтів з хронічною хворобою нирок (ХХН). Дефіцит вітаміну D асоційований з мінерально-кістковими розладами, в тому числі й остеопорозом. Сучасні міжнародні настанови рекомендують додатковий прийом вітаміну D хворим на ХХН та серед населення в цілому. Проте вплив різних форм вітаміну D на здоров’я кісток у пацієнтів з ХХН залишається неясним. Кілька рандомізованих контрольованих досліджень оцінювали вплив прийому вітаміну D на мінеральну щільність кісткової тканини та маркери обміну кісткової тканини; однак результати цих досліджень неоднорідні. Цей огляд мав на меті представити всеосяжні та сучасні результати щодо впливу нативних добавок вітаміну D на кісткові біомаркери та мінеральну щільність кісткової тканини у хворих на ХХН. Ми прийшли до висновку, що лікування вітаміном D може покращити деякі біомаркери кісток, особливо у пацієнтів з ХХН на переддіалізній стадії, із серйозним дефіцитом вітаміну D. Наші висновки також привертають увагу до важливості застосування вітаміну D у лікуванні хворих на ХХН. Однак для отримання чітких висновків важливо розробити якісні та комплексні контрольовані дослідження.

Завантаження

Дані завантаження ще не доступні.

Посилання

Ammirati AL. Chronic kidney disease. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. doi:10.1590/1806-9282.66.S1.3. 

Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-917. doi:10.1016/s0140-6736(17)30788-2. 

Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, Altiparmak MR et al. A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study. Nephrol Dial Transplant. 2011 Jun;26(6):1862-71. doi:10.1093/ndt/gfq656. 

Swartling O, Rydell H, Stendahl M, Segelmark M, Trolle Lagerros Y, Evans M. CKD progression and mortality among men and women: A nationwide study in Sweden. Am J Kidney Dis. 2021 Aug;78(2):190-9.e1. doi: 10.1053/j.ajkd.2020.11.026. 

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – A systematic review and meta-Analysis. Plos One. 2016 Jul 6;11(7):e0158765. doi: 10.1371/journal.pone.0158765. 

Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018 Jun 1;96(6):414-22d. doi: 10.2471/blt.17.206441. 

Yiğit V. Türkiye'de diyaliz ve böbrek transplantasyonu tedavisinin maliyet etkililik analizi. Mehmet Akif Ersoy Üniversitesi Sosyal Bilimler Enstitüsü Dergisi. [Internet]. 2015 Nov 1;1(13):182-205. Available from: https://dergipark.org.tr/tr/download/article-file/181877. 

Korkmaz ÖP, Kadıoğlu P. Kronik böbrek hastalığında osteoporoz ve tedavisi. Turkiye Klinikleri J Nephrol. 2018;11(1):75-80.

Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. 2021 Sep;73(3):509-29. doi: 10.1007/s12020-021-02735-9. 

Casado E, Bover J, Gómez-Alonso C, Navarro-González JF. Osteoporosis in chronic kidney disease: A essential challenge. Med Clin (English Edition). 2022 Jan 7;158(1):27-34. doi: 10.1016/j.medcli.2021.05.007. 

Wu CC, Liao MT, Hsiao PJ, Lu CL, Hsu YJ, Lu KJ, et al. Antiproteinuria effect of calcitriol in patients with chronic kidney disease and vitamin d deficiency: a randomized controlled study. J Ren Nutr. 2020 May;30(3):200-7. doi: 10.1053/j.jrn.2019.09.001. 

Zappulo F, Cappuccilli M, Cingolani A, Scrivo A, Chiocchini AL, Nunzio MD, et al. Vitamin D and the kidney: two players, one console. Int J Mol Sci. 2022 Aug 15;23(16):9135. doi: 10.3390/ijms23169135. 

Keung L, Perwad F. Vitamin D and kidney disease. Bone Rep. 2018 Dec 1;9:93-100. doi: 10.1016/j.bonr.2018.07.002. 

Shen Q, Bi X, Ling L, Ding W. 1,25-Dihydroxyvitamin D3 attenuates angiotensin ii-induced renal injury by inhibiting mitochondrial dysfunction and autophagy. Cell Physiol Biochem. 2018 Nov 30;51(4):1751-62. doi: 10.1159/000495678. 

Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney disease. Ethn Dis. [Internet]. 2009 Autumn;19(4 Suppl 5):S5-8-11. Available from: https://pubmed.ncbi.nlm.nih.gov/20077598/. 

Liu C, Li H. Correlation of the severity of chronic kidney disease with serum inflammation, osteoporosis and vitamin D deficiency. Exp Ther Med. 2019 Jan; 17(1):368-72. doi: 10.3892/etm.2018.6916. 

Jhee JH, Nam KH, An SY, Cha MU, Lee M, Park S, et al. Severe vitamin D deficiency is a risk factor for renal hyperfiltration. Am J Clin Nutr. 2018 Dec 1;108(6):1342-51. doi: 10.1093/ajcn/nqy194. 

Goto NA, Weststrate ACG, Oosterlaan FM, Verhaar MC, Willems HC, Emmelot-Vonk MH, et al. The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. Osteoporosis Int. 2020 Jan;31(1):13-29. doi: 10.1007/s00198-019-05190-5. 

Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect of vitamin d supplementation on bone metabolic markers in chronic kidney disease. J Bone Miner Res. 2018 Mar;33(3):404-9. doi: 10.1002/jbmr.3314. 

Kruger MC, Chan YM, Lau LT, Lau CC, Chin YS, Kuhn-Sherlock B, et al. Calcium and vitamin D fortified milk reduces bone turnover and improves bone density in postmenopausal women over 1 year. Eur J Nutr. 2018 Dec;57(8):2785-94. doi: 10.1007/s00394-017-1544-6. 

Saponaro F, Saba A, Zucchi R. An update on vitamin D metabolism. Int J Mol Sci. 2020 Sep 8;21(18):6573. doi: 10.3390/ijms21186573. 

Negrea L. Active vitamin D in chronic kidney disease: Getting Right Back Where We Started from? Kidney Dis. 2019 Mar;5(2):59-68. doi: 10.1159/000495138. 

Christakos S, Li S, De La Cruz J, Bikle DD. New developments in our understanding of vitamin D metabolism, action and treatment. Metabolism. 2019 Sep 1;98:112-20. doi: 10.1016/j.metabol.2019.06.010. 

Rayego-Mateos S, Doladé N, García-Carrasco A, Diaz-Tocados JM, Ibarz M, Valdivielso JM. The increase in FGF23 induced by calcium is partially dependent on vitamin D signaling. Nutrients. 2022 Jun 22;14(13):2576. doi: 10.3390/nu14132576. 

Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol (Lausanne). 2018 May 28;9:267. doi: 10.3389/fendo.2018.00267. 

Lips P, Eekhoff M, van Schoor N, Oosterwerff M,de Jong R, Krul-Poel Y, et al. Vitamin D and type 2 diabetes. J Steroid Biochem Mol Biol. 2017 Oct;173:280-5. doi: 10.1016/j.jsbmb.2016.11.021. 

Hong HH, Hong A, Wang CC, Huang EW, Chiang CC, Yen TH, et al. Calcitriol exerts a mineralization-inductive effect comparable to that of vitamin C in cultured human periodontium cells. Am J Transl Res. [Internet]. 2019 Apr 15;11(4):2304-2316. Available from: https://pubmed.ncbi.nlm.nih.gov/31105837/. 

Liu H, Cui J, Feng W, Lv S, Du J, Sun J, et al. Local administration of calcitriol positively influences bone remodeling and maturation during restoration of mandibular bone defects in rats. Mater Sci Eng C Mater Biol Appl. 2015 Apr;49:14-24. doi: 10.1016/j.msec.2014.12.064. 

Capelli I, Cianciolo G, Gasperoni L, Galassi A, Ciceri P, Cozzolino M. Nutritional vitamin D in CKD: Should we measure? Should we treat? Clin Chim Acta. 2020 Feb;501:186-97. doi: 10.1016/j.cca.2019.11.010. 

Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zennettino AC, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone. 2007 Jun;40(6):1517-28. doi: 10.1016/j.bone.2007.02.024. 

Bover J, Egido J, Ferández-Giráldez E, Praga M, Solozabal-Campos C, Torregrosa JV, et al. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. Nefrología (English Edition). 2015 Jan;35(1):28-41. doi: 10.3265/Nefrologia.pre2014.Sep.11796. 

Brandenburg V, Ketteler M. Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients. 2022 Jul 22;14(15):3009. doi: 10.3390/nu14153009. 

Lu CL, Yeih DF, Hou YC, Jow GM, Li ZY, Liu WC, et al. The emerging role of nutritional vitamin d in secondary hyperparathyroidism in CKD. Nutrients. 2018 Dec 3;10(12):1890. doi: 10.3390/nu10121890. 

Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management. JAMA. 2019 Oct 1;322(13):1294. doi: 10.1001/jama.2019.14745. 

Lee SW, Russell J, Avioli LV. 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol: conversion impaired by systemic metabolic acidosis. Science. 1977 Mar 11;195(4282):994-6. doi: 10.1126/science.841324. 

Cashman KD, Van Den Heuvel EG, Schoemaker RJ, Prévéraud DP, Macdonald HM, Arcot J. 25-Hydroxyvitamin D as a biomarker of vitamin d status and its modeling to inform strategies for prevention of vitamin d deficiency within the population. Adv Nutr. 2017 Nov 15;8(6):947-57. doi: 10.3945/an.117.015578.

Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Berisha AT, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020 Nov;74(11):1498-1513. doi: 10.1038/s41430-020-0558-y. 

Park J, Ryu S-Y, Han M-A, Choi S-W. The association of vitamin D with estimated glomerular filtration rate and albuminuria: 5th Korean National Health and Nutritional Examination Survey 2011-2012. J Ren Nutr. 2016 Nov;26(6):360-6. doi: 10.1053/j.jrn.2016.07.003. 

Niculescu DA, Deacu LG, Caragheorgheopol A, Popescu N, Ghemigian A, Procopiuc C, et al. Combined effects of vitamin D status, renal function and age on serum parathyroid hormone levels. Front Endocrinol. 2021 Apr 30;12:657991. doi: 10.3389/fendo.2021.657991. 

Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007 Oct;72(8):1004-13. doi: 10.1038/sj.ki.5002451. 

Feehan O, Armstrong D, Magee P, Pourshahidi KL, Strain JJ, Beggan L, et al. Vitamin D and bone health of older adults within care homes: An observational study. Nutrients. 2022 Jun 28;14(13):2680. doi: 10.3390/nu14132680. 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. 

Hsu C-Y, Chen L-R, Chen K-H. Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci. 2020 Sep 18;21(18):6846. doi: 10.3390/ijms21186846. 

Bellorin-Font E, Rojas E, Martin KJ. Bone Disease in chronic kidney disease and kidney transplant. Nutrients. 2023 Dec 29;15(1):167. doi: 10.3390/nu15010167. 

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun;69(11):1945-53. doi: 10.1038/sj.ki.5000414. 

Hall RK, Sloane R, Pieper C, van Houtven C, LaFleur J, Adler R, et al. Competing risks of fracture and death in older adults with chronic kidney disease. J Am Geriatr Soc. 2018 Mar;66(3):532-538. doi: 10.1111/jgs.15256. 

Torres PAU, Cohen-Solal M. Evaluation of fracture risk in chronic kidney disease. J Nephrol. 2017 Oct;30(5):653-61. doi: 10.1007/s40620-017-0398-6. 

Khairallah P, Nickolas TL. Updates in CKD-associated osteoporosis. Curr Osteoporos Rep. 2018 Dec;16(6):712-23. doi: 10.1007/s11914-018-0491-3. 

Gómez-Islas VE, García-Fong KR, Aguilar-Fuentes RE, Hernández-Castellanos S, Pherez-Farah A, Méndez-Bribiesca SA, et al. Evaluation of bone densitometry by dual-energy x-ray absorptiometry as a fracture prediction tool in women with chronic kidney disease. Bone Rep. 2020 Dec;13:100298. doi: 10.1016/j.bonr.2020.100298. 

West SL, Lok CE, Langsetmo L, Cheung AM, Szabo E, Pearce D, et al. Retracted: bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015 May;30(5):913-919. doi: 10.1002/jbmr.2406. 

Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003 Jul;14(7):570-6. doi: 10.1007/s00198-003-1435-y. 

Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006 Nov;17(11):3223-32. doi: 10.1681/asn.2005111194. 

Miller PD. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep. 2014 Jun 25;3:542. doi: 10.1038/bonekey.2014.37. 

Hsu C-Y, Cummings SR, McCulloch CE, Chertow GM. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int. 2002 May;61(5):1814-20. doi: 10.1046/j.1523-1755.2002.00306.x. 

Kuipers AL, Egwuogu H, Evans RW, Patrick AL, Youk A, Bunker CH, et al. Renal function and bone loss in a cohort of Afro-Caribbean men. J Bone Miner Res. 2015 Dec;30(12):2215-20. doi: 10.1002/jbmr.2562. 

Tasnim N, Dutta P, Nayeem J, Masud P, Ferdousi A, Ghosh AS, et al. Osteoporosis, an inevitable circumstance of chronic kidney disease: A systematic review. Cureus. 2021 Oct 5;13(10):e18488. doi: 10.7759/cureus.18488. 

Orlic L, Crncevic Z, Pavlovic D, Zaputovic L. Bone mineral densitometry in patients on hemodialysis: difference between genders and what to measure. Ren Fail. 2010;32(3):300-8. doi: 10.3109/08860221003611661. 

Tariq MH, Sulaiman SA. Prevalence of osteopenia and osteoporosis among chronic kidney disease patients: A systematic review. Open Urol Nephrol J. 2020 May 23;13(1):5-12. doi: 10.2174/1874303x02013010005. 

Yucel Kocak S, Ozdemir A. Comparison of bone mineral density and biochemical factors in hemodialysis and peritoneal dialysis patients. Clin Nephrol. 2022 Sep;98(3):115-22. doi: 10.5414/cn110729. 

Nazzal Z, Khader S, Zawyani H, Abdallah M, Sawalmeh O, Hamdan Z. Bone mineral density in Palestinian patients with end-stage renal disease and the related clinical and biochemical factors: Cross-sectional study. Plos One. 2020 Nov 12;15(11):e0241201. doi: 10.1371/journal.pone.0241201. 

Lv J, Xie W, Wang S, Zhu Y, Wang Y, Zhang P, et al. Associated factors of osteoporosis and vascular calcification in patients awaiting kidney transplantation. Int Urol Nephrol. 2023 Apr 24;55:3217-24. doi: 10.1007/s11255-023-03606-0. 

Cardwell G, Bornman J, James A, Black L. A review of mushrooms as a potential source of dietary vitamin D. Nutrients. 2018 Oct 13;10(10):1498. doi: 10.3390/nu10101498. 

Ziemińska M, Sieklucka B, Pawlak K. Vitamin K and D supplementation and bone health in chronic kidney disease—apart or together? Nutrients. 2021 Mar 1;13(3):809. doi: 10.3390/nu13030809. 

Dominguez LJ, Farruggia M, Veronese N, Barbagallo M. Vitamin D sources, metabolism, and deficiency: available compounds and guidelines for its treatment. Metabolites. 2021 Apr;11(4):255. doi: 10.3390/metabo11040255. 

de la Guía-Galipienso F, Martínez-Ferran M, Vallecillo N, Lavie CJ, Sanchis-Gomar F, Pareja-Galeano H. Vitamin D and cardiovascular health. Clin Nutr. 2021 May;40(5):2946-57. doi: 10.1016/j.clnu.2020.12.025. 

U.S. Department of Agriculture, Agricultural Research Service. FoodData Central. [Internet] 2019. Available from: fdc.nal.usda.gov. 

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Dietary reference values for vitamin D. EFSA Journal. 2016 Oct 28;14(10):e04547. doi: 10.2903/j.efsa.2016.4547. 

Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, Leboff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016 Jan;27(1):367-76. doi: 10.1007/s00198-015-3386-5. 

Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012 Oct;23(10):2479-87. doi: 10.1007/s00198-011-1868-7. 

Christodoulou M, Aspray TJ, Schoenmakers I. Vitamin D supplementation for patients with chronic kidney disease: A systematic review and meta-analyses of trials investigating the response to supplementation and an overview of guidelines. Calcif Tissue Int. 2021 Aug;109(2):157-78. doi: 10.1007/s00223-021-00844-1. 

Bover J, Ureña-Torres P, Laiz Alonso AM, Torregrosa JV, Rodríguez-García M, Castro-Alonso C, et al. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. Nefrologia (Engl Ed). 2019 May-Jun;39(3):227-42. doi: 10.1016/j.nefro.2018.10.009. 

Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201. doi: 10.1016/s0272-6386(03)00905-3. 

Yadav AK, Kumar V, Banerjee D, Gupta KL, Jha V. Effect of vitamin D supplementation on serum sclerostin levels in chronic kidney disease. J Steroid Biochem Mol Biol. 2018 Jun;180:15-18. doi:10.1016/j.jsbmb.2018.01.007. 

Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016 Sep 28;44(4):316-25. doi: 10.1159/000450766. 

Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao Li, Salles KS, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012 Sep;96(3):672-9. doi: 10.3945/ajcn.112.040642. 

Westerberg PA, Sterner G, Ljunggren Ö, Isaksson E, Elvarson F, Dezfoolian H, et al. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant. 2018 Mar 1;33(3):466-71. doi: 10.1093/ndt/gfx059. 

Kendrick J, Andrews E, You Z, Moreau K, Nowak KL, Farmer-Bailey H, et al. Cholecalciferol, calcitriol, and vascular function in CKD: A randomized, double-blind trial. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1438-46. doi: 10.2215/cjn.01870217. 

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/cjn.10661013. 

Prasad V, Cifu A. Eliminating chronic kidney disease… as a diagnosis. Pol Arch Med Wewn. 2014;124(1-2):7-9. doi: 10.20452/pamw.2067. 

Wang AY-M, Fang F, Chan J, Wen YY, Qing S, Chan I-HS, et al. Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. J Am Soc Nephrol. 2014 Jan;25(1):175-86. doi: 10.1681/ASN.2013010103. 

Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012 Jan;59(1):58-66. doi: 10.1053/j.ajkd.2011.06.027. 

Obi Y, Yamaguchi S, Hamano T, Sakaguchi Y, Shimomura A, Namba-Hamano T, et al. Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial. Sci Rep. 2020 Sep 23;10(1):15500. doi: 10.1038/s41598-020-72385-w. 

Mose FH, Vase H, Larsen T, Kancir AS, Kosierkiewic R, Jonczy B, et al. Cardiovascular effects of cholecalciferol treatment in dialysis patients – a randomized controlled trial. BMC Nephrol. 2014 Mar 24;15(1):50. doi: 10.1186/1471-2369-15-50. 

Ramirez-Sandoval JC, Arvizu-Hernandez M, Cruz C, Vazquez-Cantu B, Rojas-Concha LJ, Tamez L, et al. Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: A randomized clinical trial. J Nephrol. 2019 Aug;32:645-59. doi: 10.1007/s40620-019-00599-x. 

Russo D, Battaglia Y. Clinical significance of FGF-23 in patients with CKD. Int J Nephrol. 2011;2011:364890. doi: 10.4061/2011/364890. 

Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 Jun;79(12):1370-78. doi: 10.1038/ki.2011.47. 

Karimi E, Bitarafan S, Mousavi SM, Zargarzadeh N, Mokhtari P, Hawkins J, et al. The effect of vitamin D supplementation on fibroblast growth factor‐23 in patients with chronic kidney disease: A systematic review and meta‐analysis. Phytother Res. 2021 Oct;35(10):5339-51. doi: 10.1002/ptr.7139. 

Bosworth C, de Boer IH. Impaired vitamin D metabolism in CKD. Semin Nephrol. 2013 Mar;33(2):158-68. doi: 10.1016/j.semnephrol.2012.12.016. 

Tsujita M, Doi Y, Obi Y, Hamano T, Tomosugi T, Futamura K, et al. Cholecalciferol supplementation attenuates bone loss in incident kidney transplant recipients: A prespecified secondary endpoint analysis of a randomized controlled trial. J Bone Min Res. 2022 Feb;37(2):303-11. doi: 10.1002/jbmr.4469. 


Переглядів анотації: 763
Завантажень PDF: 499
Опубліковано
2023-12-02
Як цитувати
Демірель, С., & Гюрбюз, М. (2023). Роль лікування вітаміном D у клінічній оцінці остеопорозу у хворих на хронічну хворобу нирок. Український Журнал Нефрології та Діалізу, (1(81), 71-85. https://doi.org/10.31450/ukrjnd.1(81).2024.09
Номер
№ 1(81) (2024): Український журнал нефрології та діалізу
Розділ
Школа нефролога

Авторське право (c) 2024 Український Журнал Нефрології та Діалізу

Creative Commons License

TЦя робота ліцензується відповідно до Creative Commons Attribution-ShareAlike 4.0 International License.